FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

vvasinigton,	D.C. 20040	

OMB APPROVAL

Check this box if no longer subject to							
Section 16. Form 4 or Form 5							
obligations may continue. See							
Instruction 1(h)							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number:	3235-0287
Estimated average b	ourden
hours per response:	0.5

Name and Address of Reporting Person* LEWIS JONATHAN			2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)																
LEWIS JOINATHAN														Director			10% O	vner	
(Last) 1180 AV) (First) (Middle)) AVENUE OF THE AMERICAS, 19TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 09/13/2005)	X Officer (give title Other (specify below) CEO					
(Street) NEW Y	et) W YORK NY 10036				4. If Amendment, Date of Original Filed (Month/Day/Year) 09/15/2005								Line)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	State)	(Zip)											Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		e, Transaction Disposed Code (Instr. 5)		rities Acquired (A) o d Of (D) (Instr. 3, 4			5. Amoun Securities Beneficia Owned Fo Reported	s Fo ally (D) ollowing (I)			7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)		'		(111501.4)		
Common Stock, \$.001 par value								(0										
			Table II - I								osed of				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	′ Co		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		е	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	e s Illy	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Co	de V	,	(A)	(D)	Date Exercisa		Expiration Date	Title	O N	mount r umber f Shares		Transaction(s) (Instr. 4)			
Stock Option (right to buy)	\$0.08	09/13/2005		J(1)		25,674		(2)		01/08/2014	Comm		25,674	(1)	25,67	'4	D	
Stock Option (right to buy)	\$0.08	09/13/2005		J	1)		242,979		(4)		01/27/2014	Comm Stocl		42,979	(1)	242,97	79	D	
Stock Option (right to buy)	\$4.31 ⁽³⁾	09/13/2005		J(1)		87,789		(5)		06/08/2015	Comm Stocl		37,789	(1)	87,78	9	D	
Stock Option (right to	\$4.31 ⁽³⁾	09/13/2005		J((6)		54,161		(7)		09/13/2015	Comm Stocl		54,161	\$0	54,16	1	D	

Explanation of Responses:

buy)

- 1. Received in exchange for options to acquire shares of common stock of ZIOPHARM, Inc. in connection with a merger transaction involving ZIOPHARM, Inc. with ZIOPHARM Oncology, Inc. (f/k/a EasyWeb, Inc.) (the "Merger").
- 2. 8,558 shares vest on each of 1/8/05, 1/8/06 and 1/8/07.
- 3. Amendment filed to correct option exercise price mistated in previously filed Form.
- 4. 80,993 shares vest on each of 1/27/05, 1/27/06 and 1/27/07.
- 5. 29,263 shares vest on each of 6/8/05, 1/27/06 and 1/27/07.
- 6. Received pursuant to anti-dilution rights triggered upon the Merger.
- $7.\,18,\!054$ shares vest on each of 9/13/05 and 1/27/06; $18,\!053$ shares vest on 1/27/07.

04/26/2006 /s/ Jonathan Lewis

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.